Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Extension Study of Ataluren (PTC124®) in Subjects With Nonsense-Mutation-Mediated Cystic Fibrosis

NCT01140451 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT01140451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01140451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Extension Study of Ataluren (PTC124®) in Subjects With Nonsense-Mutation-Mediated Cystic Fibrosis
Lead sponsor
PTC Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
August 12, 2010
Completion date
December 2, 2013
Enrollment
191 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis